• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Efficacy and safety of Mianyi granules (免疫Ⅱ顆粒) for reversal of immune nonresponse following antiretroviral therapy of human immunodeficiency virus-1:a randomized,double-blind,multi-center,placebo-controlled trial

    2022-07-20 15:54:06LIUYingZOUWenXIANQingfeiDENGXinZHANGFuchunWANGLiLIYonghongLUNWenhuiWANGJian
    關鍵詞:顆粒

    LIU Ying,ZOU Wen,XIAN Qingfei,DENG Xin,ZHANG Fuchun,WANG Li,LI Yonghong,LUN Wenhui,WANG Jian

    LIU Ying,ZOU Wen,XIAN Qingfei,WANG Jian,Traditional Chinese Medicine Center for Acquired Immune Deficiency Syndrome Prevention and Treatment,China Academy of Chinese Medical Sciences,Beijing 100700,China

    DENG Xin,Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine,Nanning 530011,China

    ZHANG Fuchun,Infectious Disease Department of Guangzhou Eighth People’s Hospital,Guangzhou 510060,China

    WANG Li,Internal Medicine Department of Traditional Chinese Medicine,Yunnan Provincial Academy of Traditional Chinese Medicine,Kunming 650031,China

    LI Yonghong,Department of Hepatology,Shenyang Sixth People’s Hospital,Shenyang 110006,China

    LUN Wenhui,Department of Dermatology,Beijing Ditan Hospital,Beijing 100015,China

    Abstract OBJECTIVE:To investigate whether Mianyi granules (免疫Ⅱ顆粒) are effective and safe in reversing immune nonresponse following antiretroviral therapy (ART) in individuals with human immunodeficiency virus (HIV)infection.METHODS:Randomized,double-blind,multi-center,placebo-controlled trial (factorial design) of daily oral Mianyi granules versus placebo for 72 weeks.A total of 361 HIV-positive individuals receiving ART at five Class III Grade I hospitals in China between September 2013 and January 2016 completed the study.The primary endpoints were frequencies of CD3+,CD4+,CD8+,and CD45RA+cells at seven timepoints over the 72 weeks.Secondary endpoints included viral loads,clinical symptoms,and quality of life at 72 weeks.RESULTS:A total of 400 participants were enrolled in the study and randomized,of whom 361 completed the study:189 individuals (140 men and 49 women) in the Mianyi granule group and 172 individuals (135 men and 37 women) in the placebo group.In the intent-to-treat population,CD4+T cell counts increased from (193 ± 71)cells/mm3 at baseline to (288 ± 131) cells/mm3 posttreatment in the Mianyi granule group and from (200 ± 75)cells/mm3 at baseline to (264 ± 124) cells/mm3 posttreatment in the placebo group.Patients treated with Mianyi granule had higher increases in CD4+T cell counts than those treated with placebo (P=0.045).Reversal of immune nonresponse was defined as a CD4+T cell increase of more than 100 cells/mm3.After treatment for 72 weeks,Mianyi granule was effective in reversing immune nonresponse in a higher proportion of individuals (20.2%) compared with placebo (9.7%).CD45RA+cell counts increased from (34 ± 32) cell/mm3 at baseline to (51 ± 61) cells/mm3 post-treatment in the Mianyi granule group and from (37 ± 33) cells/mm3 at baseline to (48 ± 37) cells/mm3 post-treatment in the placebo group.Mianyi granules were more effective than placebo in increasing CD45RA+cell counts.CONCLUSIONS:In ART-treated HIV-positive adults with immune nonresponse,treatment with Mianyi granules for 72 weeks was safe and significantly increased CD4+and CD45RA+cell counts,thereby promoting immune reconstitution.

    Keywords:HIV-1;immunity;antiretroviral therapy;treatment outcome;safety;Mianyi granules

    In patients with human immunodeficiency virus (HIV)infection and acquired immunodeficiency syndrome(AIDS),antiretroviral therapy (ART) typically results in diminished viral replication,increased CD4+T cell counts,reversal of most immunological disturbances,and reduced risks of morbidity and mortality.1Although ART causes a rapid reduction in HIV RNA viral loads and restoration of CD4+T-cell numbers in most patients,up to 40% of patients receiving HAART experience incomplete immune recovery despite sustained viral suppression.2-4Alternative approaches to promote immune reconstitution are urgently necessary.

    Traditional Chinese medicine (TCM) plays a unique role in regulating the human immune system.Promoting immune reconstitution using TCM is a major focus in HIV research.TCM can improve CD4+T cell counts,naive CD4+T cell counts,memory CD4+T cell counts,and CD45RA and/or CD45RO cell counts while simultaneously decreasing T-cell immune activation.5-9A prior study showed that Mianyi granules (免疫Ⅱ顆粒)were effective in increasing CD4+T cell counts in patients with HIV undergoing HAART.10 This trial was designed to evaluate the therapeutic effects of Mianyi granules on CD4+T cells in HIV-positive patients with incomplete immune reconstitution following ART.

    2.METHODS

    2.1.Ethics

    The study protocol was approved by the China Academy of Traditional Chinese Medicine (2013 No.001) and was registered in the Chinese Clinical Trial Registry(Registration No.ChiCTR-TRC-13003716).The study was conducted in accordance with the ethical principles laid out in the Declaration of Helsinki,the International Conference on Harmonization Tripartite Guideline on Good Clinical Practice,and local institutional guidelines.11Written informed consent was obtained from all participants.The purpose,procedures,and potential risks and benefits of the study were explained to prospective participants.

    2.2.Study design and participants

    This randomized,double-blind,placebo-controlled clinical trial consisted of a pretreatment phase (screening and a run-in visit) followed by randomization of participants into two groups.Participants in both groups underwent a 72-week treatment protocol.A cohort of 361 HIV-infected adults with incomplete immune recovery following HAART were recruited between September 2013 and January 2016 in collaboration with five Class III Grade I hospitals in China (Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine,Guangzhou Eighth People's Hospital,Yunnan Provincial Academy of Traditional Chinese Medicine,Shenyang Sixth People's Hospital,and Beijing Ditan Hospital).

    2.3.Randomization and masking

    This was a randomized,double-blind,multi-center,placebo-controlled trial conducted by the Center for AIDS Prevention and Treatment with Traditional Chinese Medicine,China Academy of Traditional Chinese Medicine.Randomization was controlled by an independent clinical research coordinator (CRC).Patients were randomly allocated at a 1∶1 ratio to the Mianyi granule group or placebo group.First,patient basic information was transmitted to an independent statistician;at this stage the randomization number was left blank.The statistician then allocated a randomization number based on the allocation sequence.The number was generated in advance using a random number creation program.The CRC then informed the investigators of the specific identification number.Investigators did not contact the CRC or statistician,and the CRC was separated from all researchers.The statistician was not allowed to contact the other researchers.

    2.4.Inclusion criteria

    Diagnosis of HIV was made using the Diagnostic Criteria for AIDS and HIV infection from the Ministry of Public Health of China (WS293-2008).All participants were confirmed to be HIV-antibody-positive by Western blotting.12Participants were between the ages of 18 and 70 years.For patients who had received HAART for more than 12 months and less than 24 months,CD4 counts had to be < 200 cells/mm3,while for those who had received HAART for more than 24 months,CD4 counts had to be < 350 cells/mm3.Additionally,viral loads had to be below the limit of detection and CD4 cell counts had to be ≥ 50 cells/mm3at baseline.

    2.5.Exclusion criteria

    Participants with serious and uncontrolled opportunistic infections as well as patients who participated in other clinical drug trials or received immunomodulatory therapy within 1 month of study entry were excluded.Patients with malignant tumors,severe hepatic or renal dysfunction,and autoimmune diseases were excluded.Pregnant or lactating women and women trying to conceive were excluded.Additionally,patients with intellectual deficiencies or psychotic disorders who could not provide valid informed consent and/or were deemed unlikely to comply with the study protocol were excluded.

    2.6.Procedures

    The randomization flow chart is shown in Figure 1.Study physicians and nurses screened individuals and conducted a run-in pre-randomization phase to obtain written informed consent,confirm eligibility,and identify potentially non-adherent individuals.Demographic characteristics were collected and participants were counseled regarding Mianyi granule adherence.

    Eligible participants were then randomly assigned to one of the study groups using the next sequential number in a randomization list generated by the Academy of Chinese Medical Sciences Data Center.

    In both groups,participants were treated with ART regimens prior to participation in the study.

    In the Mianyi granule group,participants took Mianyi granules orally twice a day,1 to 2 h after breakfast and dinner.A minimum 1-hour interval was recom-mended between taking Mianyi granules and ART.Mianyi granules were provided by Jiangyin Tianjiang Pharmaceutical Co.,Ltd.(Jiangyin,China).The batch numbers of Mianyi granules were 1311327 (first batch)and 1409358 (second batch).Mianyi granules were packaged in 5.5-g bags.

    In the placebo group,participants took placebo orally twice a day,1 to 2 h after breakfast and dinner.A minimum 1-hour interval was recommended between taking placebo and ART.The placebo was the same as Mianyi granules in appearance and taste and was provided by Jiangyin Tianjiang Pharmaceutical Co.,Ltd.(Jiangyin,China).

    All granules were indistinguishable in shape,size,and color.Bags containing granules were prelabeled by the pharmacist for the entire study period with identification numbers according to the assignment list using doubleblind masking.During monthly visits,the remaining granules from the previous month were counted to assess adherence.

    2.7.Outcomes

    The primary endpoints were CD3/CD8/CD45/CD4 cell counts at 72 weeks.Secondary endpoints included viral load,clinical symptoms,and quality of life measured using the World Health Organization (WHO) Quality of Life Scale at 72 weeks.These parameters were assessed by each study sub-center.

    2.8.Safety evaluation

    Safety indices included laboratory parameters (red blood cell count,white blood cell,aspartate transaminase,alanine aminotransferase,blood urea nitrogen,and serum creatinine),electrocardiography,and a general physical examination at 72 weeks.These parameters were assessed by each research center.

    2.9.Statistical analysis

    Statistical analyses were performed using SAS 9.1 statistical software (SAS Institute,Cary,NC,USA).All statistical tests were two-sided.Data were presented as mean ± standard deviation ().Differences between groups were assessed usingT-tests or nonparametric tests.Differences within groups before and after intervention were assessed using pairedt-tests.Differences in symptom frequency were assessed usingt-tests and differences in rank order were assessed using the Cochran-Mantel-Haenszel test.Values ofP <0.05 were considered statistically significant.

    2.10.Data and safety monitoring

    The Data Safety Monitoring Board reviewed the unblended safety and efficacy data before the initiation of the study,annually,at the study midpoint,and at the end of the study.The early stopping boundaries were based on nominal values ofP <0.001 for efficacy endpoints andP <0.05 for safety endpoints.11All adverse events (AEs) were characterized using the AE form rating scale as follows:1,remote;2,possible;3,probable;and 4,definite.13

    3.RESULTS

    Of 1156 patients with HIV infection screened,396 were randomized and 361 completed the study (Figure 1).The demographic characteristics of the Mianyi granule group were as follows (mean ± standard deviation):age (44 ±11) years,height (166 ± 8) cm,and weight (59 ± 8) kg.The demographic characteristics of the placebo group were as follows:age (44 ± 11) years,height (167 ± 7) cm,and weight (60 ± 9) kg.There were no statistically significant baseline differences between the two groups in immune indices,symptoms and signs,body temperature,heart rate,respiration rate,or blood pressure(P >0.05).Baseline demographic characteristics were similar in the two groups.

    Figure 1 Study flow diagram

    Frequencies of CD4 cells increased in both groups after treatment for 72 weeks,but this increase was significantly more pronounced in the Mianyi granule group (193 ± 71) cells/mm3at baselinevs(288 ± 131)cells/mm3post-treatment) compared with the placebo group (200 ± 75) cells/mm3at baselinevs(264 ± 124)cells/mm3post-treatment) (P=0.045).Differences in CD4 cell increases from baseline between study arms were observed at other time points post-treatment as well(Table 2).

    Effective treatment was first defined as CD4 cell count increases of more than 50 cells/mm3.CD4 cell counts increased by more than 50 cells/mm3compared with baseline in both groups at various time points.In the Mianyi granule arm,the number of patients with changes in CD4 cell counts of more than 50 cells/mm3gradually increased over time,while in the placebo arm this was not the case.After treatment for 72 weeks,administration of Mianyi granule was effective in 47.5% of participants while placebo was effective in only 31.3% of participants(Table 3).

    Next,we applied a more stringent definition of effective treatment (increase in CD4 cell count of more than 100 cells/mm3).CD4 cell counts increased by more than 100 cells/mm3compared with baseline in both groups at various time points.In the Mianyi granule arm,the number of patients with changes with CD4 cell counts of more than 100 cells/mm3gradually increased over time,particularly after treatment for 48,60,and 72 weeks.In the control arm,no such trends were observed.After treatment for 72 weeks,administration of Mianyi granule was effective in 20.2% of participants while administration of placebo was effective in only 9.7% of participants (Table 4).

    Table 1 Enrolment and completion cases at each study center (n)

    Table 2 Comparison of CD4 cell counts (cells/mm3) at baseline and post-treatment in patients receiving Mianyi granule or placebo ()

    Table 2 Comparison of CD4 cell counts (cells/mm3) at baseline and post-treatment in patients receiving Mianyi granule or placebo ()

    Notes:treatment group:the Mianyi granules+HAART,the Mianyi granules take 5.5-g twice a day for 72 weeks;control group:the placebo +HAART,the placebo take 5.5-g twice a day for 72 weeks.P:treatment group compared with control group.

    The CD4/CD8 ratio showed no significant differences between the two groups.However,in the Mianyi granule group there was a suggestion of a rapid increase in the CD4/CD8 ratio starting from 36 weeks post-treatment(Table 5).CD45RA cell counts were increased in both groups after treatment for 72 weeks.CD45RA counts increased to a greater degree in patients receiving Mianyi granule(33.87 ± 32.15 cells/mm3at baseline and 52.82 ±61.53 cells/mm3post-treatment) compared with placebo (36.75 ± 32.94 cells/mm3at baseline and 48.27± 36.91 cells/mm3post-treatment) (P=0.035).At other time points,increases from baseline in CD45RA cell counts were observed in the Mianyi granule group but not in the placebo group (Table 6).

    Table 3 Participants whose CD4 cells increased or decreased by more than 50 cells/mm3 (n)

    Table 4 Participants whose CD4 cells increased or decreased by more than 100 cells/mm3 (n)

    Table 5 Comparison of CD4/CD8 ratios at baseline and post-treatment in patients receiving Mianyi granule or placebo ()

    Table 5 Comparison of CD4/CD8 ratios at baseline and post-treatment in patients receiving Mianyi granule or placebo ()

    Notes:treatment group:the Mianyi granules+ART,the Mianyi granules take 5.5-g twice a day for 72 weeks;control group:the placebo +ART,the placebo take 5.5-g twice a day for 72 weeks.P:treatment group compared with control group.

    A survival curve was generated to display CD4 cell count restoration,which was defined as an increase of 30%compared with baseline (Figure 2).In the figure,the xaxis shows time and the y-axis shows the percentage of patients in whom treatment was ineffective (increase in CD4 cell counts of less than 30%).At baseline,the survival curves for the two groups coincided,and remained basically the same at 20 weeks post-treatment.Over time,the distance between the two groups gradually widened,showing that treatment with Mianyi granules was ineffective in far fewer participants compared with placebo.

    Figure 2 Survival analysis of CD4 cell count restoration (30%increase) in patients treated with Mianyi granules or placebo

    TCR-γ-f2 receptor gene fragment diversity (mean D value of PCR product dispersion) was compared in the two groups.In the Mianyi granule group,the mean D value for TCR-γ-f2 receptor gene fragment diversity was significantly lower post-treatment compared with baseline (pairedttest,P <0.05).In the placebo group,the mean D value for TCR-γ-f2 receptor gene fragment was significantly lower compared with baseline (paired t test,P <0.05).Post-treatment changes in TCR-γ-f2 receptor gene fragment diversity were similar in both groups(ttest,P=0.145) (Table 7).Thus,TCR-γ-f2 receptor gene fragment diversity post-Mianyi granule treatment was significantly lower than before treatment.Diversity was greatly improved,indicating that the function of mucosal immune γδ-T cells in patients receiving Mianyi granules was improved and restored.

    There were no statistically significant differences in the frequencies of symptoms between the two groups (Table 7).

    There were no statistically significant differences in theWHO Quality of Life Scale results between the two groups (Table 8).

    Table 6 Comparison of CD45RA (cells/mm3) at baseline and post-treatment in patients receiving Mianyi granule or placebo ()

    Table 6 Comparison of CD45RA (cells/mm3) at baseline and post-treatment in patients receiving Mianyi granule or placebo ()

    Notes:treatment group:the Mianyi granules+ART,the Mianyi granules take 5.5-g twice a day for 72 weeks;control group:the placebo +ART,the placebo take 5.5-g twice a day for 72 weeks. P:treatment group compared with control group.

    Safety evaluation

    During the 72 weeks of treatment,a total of 18 AEs were reported.The frequency of AEs in the Mianyi granule group was 4.76% compared with 6.40% in the placebo group (Table 9).

    Table 7 Comparison of symptom frequency at baseline and post-treatment in patients receiving Mianyi granule or placebo ()

    Table 7 Comparison of symptom frequency at baseline and post-treatment in patients receiving Mianyi granule or placebo ()

    Notes:treatment group:the Mianyi granules+ART,the Mianyi granules take 5.5-g twice a day for 72 weeks;control group:the placebo +ART,the placebo take 5.5-g twice a day for 72 weeks.P:treatment group compared with control group.

    Table 8 Comparison of WHO Quality of Life Scale results in patients receiving Mianyi granules or placebo ()

    Table 8 Comparison of WHO Quality of Life Scale results in patients receiving Mianyi granules or placebo ()

    Notes:treatment group:the Mianyi granules+ART,the Mianyi granules take 5.5-g twice a day for 72 weeks;control group:the placebo +ART,the placebo take 5.5-g twice a day for 72 weeks.P:treatment group compared with control group.

    Table 9 Adverse events in patients receiving Mianyi granules or placebo (n)

    4.DISCUSSION

    This study showed that Mianyi granules can stabilize CD4 counts and reconstitute immune function in patients with HIV/AIDS who previously received ART and experienced poor immune recovery.Mianyi granules are a component of TCM.The prescription uses Huangqi(Radix Astragali Mongolici) and Dangshen (Radix Salviae Miltiorrhizae) as the monarch medicine;Lingzhi(Ganoderma Lucidum) and Gouqizi (Fructus Lycii) as the minister medicine;and Yinyanghuo (Herba Epimedii Brevicornus),Bajitian (Radix Morindae Officinalis),and Ezhu (Rhizoma Curcumae Phaeocaulis) as the adjuvant medicine.TCM depends on strict compatibility between medicines to improve the immune function of the body by invigorating theQiin the middle-jiao,tonifying the kidneys,and nourishing bone marrow.Together,the overall effect is strengthening of human immune function.Numerous studies have shown that these components have a regulatory effect on imm-unity.14

    Based on TCM theory,the effectiveness of Mianyi granules occurs by reinforcingQi,nourishingYin,and supporting healthy energy.Some clinical observations support the notion that TCM can play an important role in immune reconstitution.15

    A cohort study of 2235 patients positive for HIV in Switzerland16who received HAART found that CD4 cell counts recovered to 500 cells/mm3in just 39% of patients.Because of the presence of viral reservoirs,HIV virions can escape from immune responses or drugs.Thus,it is difficult for HAART to suppress or clear HIV completely.It is also difficult to completely restore normal immune function following long-term HAART.For optimal prognosis of patients with HIV/AIDS receiving HAART,immune function must be fully restored.17

    Immune reconstitution is an important aspect of the management of patients with HIV/AIDS.HAART can effectively control HIV replication,permitting immune reconstitution and reducing abnormal immune activation.18CD4+T cells,which play important roles in regulating humoral and cellular immune function,are decreased in patients with HIV/AIDS through direct HIV cytotoxicity and indirect apoptosis induction mechanisms.19Restoration of immune function in patients with HIV/AIDS can stabilize the patient’s condition and improve the efficacy of existing treatments,thus improving survival and prognosis.20The combined treatment strategy of integrated TCM and Western Medicine promotes long-term reconstitution of the immune system and thus,is beneficial and has potential use for improving INR in PLWH.21Over the last 30 years,the use of TCM to treat HIV/AIDS has made significant strides and TMC now plays a key role in the battle against HIV/AIDS in China.More and more clinicians and patients are convinced of the efficacy and safety of TCM for treatment of HIV/AIDS in conjunction with HAART.22

    In conclusion,Mianyi granules could increase CD4+and CD45RA+cell counts in immune reconstitution,it is safe and effective for ART-treated HIV-positive adults with immune nonresponse.

    5.ACKNOWLEDGEMENTS

    We thank Liwen Bianji (Edanz) (www.liwenbianji.cn/)for editing the English text of a draft of this manuscript.

    6.REFERENCES

    1.Julie CG,Hans JH,Jan G,et al.Incomplete immune recovery in HIV infection:mechanisms,relevance for clinical care,and possible solutions.Clin Dev Immunol 2012;2012:670957.

    2.Kelley CF,Kitchen CM,Hunt PW,et al.Incomplete peripheral CD4+cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment.Clin Infect Dis 2009;48:787-94.

    3.Nakanjako D,Kiragga A,Ibrahim F,et al.Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa:frequency and clinical significance.AIDS Res Ther 2008;5:23.

    4.Negredo E,Massanella M,Puig J et al.Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIVinfected patients:clinical implications.Clin Infect Dis 2010;50:1300-8.

    5.Wu XF,Wang J,Li Y.Intervention of Immune 1 combined HAART on immune function in patients with HIV/AIDS reconstruction.Zhong Guo Zhong Yao Za Zhi 2013;38:2453-7.

    6.Wang J,Li Y,Tang YL,et al.Effect of immune No.2 on the immune reconstitution in patients with HIV/AIDS after highly active antiretroviral treatment:a randomized double blind placebo controlled clinical trial.Zhong Guo Jie He Yi Xue Za Zhi 2013;19:340-6.

    7.Li T,Xie J,Li Y,et al.Tripterygium wilfordii Hook F extract in cART-treated HIV patients with poor immune response:a pilot study to assess its immunomodulatory effects and safety.HIV Clin Trials 2015;16:49-56.

    8.Shao BP.Clinical research report on the efficacy and safety of Tangcao Tablets in the treatment of HIV/AIDS.Compilation of Papers of the 6th Annual Academic Conference of the AIDS Prevention and Treatment Branch of the Chinese Society of Traditional Chinese Medicine;2008 Dec;Anhui,China.2008;11:179-90.

    9.Wu H,Zhao M,Li XW,et al.Clinical observation of the efficacy and safety of Aifukang capsule in patients with HIV infections and AIDS.Zhong Guo Ai Zi Bing Xing Bing 2012;18:434-7.

    10.Wang J,Lin HSH,Li Y,et al.Effect of Mianyi No.2 formula on the symptoms and signs of HIV/AIDS Patients with insufficient immune reconstitution.Zhong Yi Za Zhi 2012;53:923-6.

    11.Hughes MD,Pocock SJ.Interim monitoring of clinical trials.In:Finkelstein DM,Schoenfeld DA,eds.AIDS Clinical Trials.Hoboken.NJ:Wiley&Sons,1995:177-96.

    12.The ministry of health standard professional committee of infectious diseases,China (2012) the diagnostic criteria of AIDS and HIV infected,Beijing,China.Zhong Guo Ai Zi Bing Xing Bing 2012;18:354-6.

    13.Department of Health and Human Services (2003) Safety reporting requirements for human drug and biological products;Proposed rule.Food and Drug;Administration Federal Register 68.

    14.Chen H,Liu X,Su YX,et al.Notch signaling pathway mediates the immunomodulatory mechanism of Yangfei Huoxue decoction alleviating bleomycin-induced pulmonary fibrosis in rats.J Tradit Chin Med 2020;40:204-11.

    15.Wang J,Lin HS,Liu MY,Li Y.lmmune reconstitution of acquired immune deficiency syndrome.Chin J Integr Med 2010;16:557-564.

    16.Kaufmann GR,Perrin L,Pantaleo G,et al.CD4+T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years:the Swiss HIV cohort study.Arch Intern Med 2003;163:2187-95.

    17.Wang J,Huang SJ.Clinical research on the combination of TCM and Western Medicine on AIDS.Beijing:People's Medical Publishing House,2007:75-6.

    18.Sun J,Wu NP,Feng TT,et al.Effect of long term highly active antiretroviral therapy on abnormal immune activation and immune reconstruction in HIV-1 infected individuals.Zhejiang Da Xue Xue Bao (Yi Xue Ban) 2010;39:618-22.

    19.Herbeuval JP,Boasso A,Grivel JC,et al.TNF-related apoptosisinducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells.Blood 2005;105:2458-64.

    20.Goicoechea M,Smith DM,Liu L,et al.Determinants of CD4+T cell recovery during suppressive antiretroviral therapy:association of immune activation,T cell maturation markers,and cellular HIV-1 DNA.J Infect Dis 2006;194:29-37.

    21.Tao Z,Huang Xj,Liu Y,et al.Efficacy of integrated Traditional Chinese Medicine and anti-retroviral therapy on immunological nonresponse in patients with human immunodeficiency virus/acquired immunodeficiency syndrome:a Meta-analysis of randomized controlled trials.J Tradit Chin Med 2021;41:669-76.

    22.Liu ZB,Wang X,Liu HJ.Treatment of acquired immunodeficiency syndrome with Chinese medicine in China:opportunity,advancement and challenges.Chin J Integr Med 2013;19:563-7.

    猜你喜歡
    顆粒
    Tenglong Buzhong granules (藤龍補中顆粒) inhibits the growth of SW620 human colon cancer in vivo
    Effectiveness and Safety of Jinye Baidu Granules(金葉敗毒顆粒) for Acute Upper Respiratory Tract Infection:A Systematic Review and Meta-analysis
    硅納米顆粒的制備及其應用
    光源與照明(2019年4期)2019-05-20 09:18:16
    要讓顆粒都歸倉
    心聲歌刊(2019年1期)2019-05-09 03:21:32
    HPLC-ELSD法同時測定十味鵝黃顆粒中3種成分
    中成藥(2018年10期)2018-10-26 03:41:04
    基于近場散射的顆粒粒徑分布測量
    疏風定喘顆粒輔料的篩選
    中成藥(2017年4期)2017-05-17 06:09:29
    HPLC法同時測定氣管炎顆粒中7種有效成分
    中成藥(2016年4期)2016-05-17 06:07:43
    納米至亞微米級鈷顆粒的合成與表征
    連花清瘟顆粒治療喉瘖30例
    国产乱人伦免费视频| 90打野战视频偷拍视频| 久久香蕉精品热| 两人在一起打扑克的视频| 亚洲国产欧美一区二区综合| 久久久精品欧美日韩精品| 国产亚洲精品久久久久5区| 日韩 欧美 亚洲 中文字幕| 一级a爱视频在线免费观看| 脱女人内裤的视频| x7x7x7水蜜桃| 免费高清视频大片| 精品久久久久久成人av| 久久久久国内视频| 国产午夜精品久久久久久| 久久亚洲精品不卡| 午夜两性在线视频| 欧美乱色亚洲激情| 亚洲精品久久午夜乱码| 夫妻午夜视频| 久久久国产成人免费| 日韩视频一区二区在线观看| 亚洲精品一二三| 欧美不卡视频在线免费观看 | 国产区一区二久久| 夜夜爽天天搞| 国产精品九九99| 黑人巨大精品欧美一区二区蜜桃| 中文亚洲av片在线观看爽| 正在播放国产对白刺激| 国产麻豆69| 老鸭窝网址在线观看| 亚洲av日韩精品久久久久久密| 国产蜜桃级精品一区二区三区| 亚洲国产精品sss在线观看 | 757午夜福利合集在线观看| 一级毛片女人18水好多| 亚洲情色 制服丝袜| √禁漫天堂资源中文www| 在线观看免费午夜福利视频| 久久久久国内视频| 99在线人妻在线中文字幕| 国产xxxxx性猛交| 久久精品91蜜桃| 757午夜福利合集在线观看| 国产亚洲精品综合一区在线观看 | 欧美一区二区精品小视频在线| 亚洲欧美一区二区三区久久| 亚洲精品av麻豆狂野| 亚洲成国产人片在线观看| 日韩有码中文字幕| 国产成人影院久久av| 人成视频在线观看免费观看| 日韩欧美免费精品| 亚洲,欧美精品.| 国产不卡一卡二| 亚洲自拍偷在线| 欧美一区二区精品小视频在线| 久久国产亚洲av麻豆专区| 国产成人av教育| 18美女黄网站色大片免费观看| 午夜亚洲福利在线播放| 黄片小视频在线播放| 成人三级黄色视频| 日韩免费高清中文字幕av| 国产极品粉嫩免费观看在线| 欧美激情 高清一区二区三区| 国产又色又爽无遮挡免费看| 亚洲成人免费电影在线观看| 女性被躁到高潮视频| 真人做人爱边吃奶动态| tocl精华| 日日干狠狠操夜夜爽| 成人亚洲精品一区在线观看| a级片在线免费高清观看视频| 黑人操中国人逼视频| 法律面前人人平等表现在哪些方面| 极品人妻少妇av视频| 制服诱惑二区| 精品久久久久久久毛片微露脸| 亚洲熟妇中文字幕五十中出 | 亚洲精品美女久久久久99蜜臀| 男女下面进入的视频免费午夜 | 啦啦啦在线免费观看视频4| 麻豆一二三区av精品| 国产精品久久电影中文字幕| aaaaa片日本免费| www.www免费av| 母亲3免费完整高清在线观看| 亚洲五月天丁香| 在线观看午夜福利视频| 欧美日韩视频精品一区| 亚洲人成电影免费在线| 日本撒尿小便嘘嘘汇集6| 首页视频小说图片口味搜索| 欧美中文综合在线视频| xxxhd国产人妻xxx| 9191精品国产免费久久| 欧美日韩瑟瑟在线播放| 侵犯人妻中文字幕一二三四区| 亚洲欧美激情在线| 精品国产亚洲在线| 热re99久久精品国产66热6| 色老头精品视频在线观看| xxx96com| 久久人妻av系列| 十分钟在线观看高清视频www| 久久久精品国产亚洲av高清涩受| 在线av久久热| 国产单亲对白刺激| 99久久综合精品五月天人人| 免费在线观看黄色视频的| 精品熟女少妇八av免费久了| 日韩一卡2卡3卡4卡2021年| 18美女黄网站色大片免费观看| 麻豆国产av国片精品| 日本一区二区免费在线视频| 18禁黄网站禁片午夜丰满| 夜夜夜夜夜久久久久| 免费久久久久久久精品成人欧美视频| 国产成人啪精品午夜网站| 久久人妻av系列| 咕卡用的链子| 美国免费a级毛片| netflix在线观看网站| av电影中文网址| 一本大道久久a久久精品| 免费一级毛片在线播放高清视频 | 成人精品一区二区免费| 国产高清videossex| 伦理电影免费视频| 欧美成人免费av一区二区三区| 欧美精品一区二区免费开放| 热99re8久久精品国产| 中文字幕色久视频| 精品日产1卡2卡| 久久久久久亚洲精品国产蜜桃av| 久久久国产一区二区| 校园春色视频在线观看| 日韩欧美在线二视频| 久久久国产成人精品二区 | 国产成人精品久久二区二区免费| 人妻丰满熟妇av一区二区三区| 丰满迷人的少妇在线观看| 国产精品一区二区在线不卡| 最近最新中文字幕大全电影3 | 午夜两性在线视频| 午夜日韩欧美国产| 国产亚洲精品一区二区www| 成人精品一区二区免费| 免费在线观看日本一区| 啦啦啦在线免费观看视频4| 一级毛片高清免费大全| xxx96com| 国产精品一区二区免费欧美| 我的亚洲天堂| 美女福利国产在线| 757午夜福利合集在线观看| 国产精品免费视频内射| 免费日韩欧美在线观看| 亚洲一区中文字幕在线| 欧美激情久久久久久爽电影 | a在线观看视频网站| 中文欧美无线码| 国产精品成人在线| 久久久精品国产亚洲av高清涩受| 老司机午夜福利在线观看视频| 校园春色视频在线观看| xxx96com| 看片在线看免费视频| 男女高潮啪啪啪动态图| 国产成人啪精品午夜网站| 久久久久国产一级毛片高清牌| 亚洲avbb在线观看| 丝袜美足系列| 咕卡用的链子| 9热在线视频观看99| 久久 成人 亚洲| 丁香六月欧美| 欧美日韩国产mv在线观看视频| 国产成人免费无遮挡视频| 精品久久久精品久久久| 一边摸一边抽搐一进一出视频| 中文亚洲av片在线观看爽| 欧美日韩亚洲高清精品| 欧美av亚洲av综合av国产av| 免费观看人在逋| 久久精品成人免费网站| av网站在线播放免费| 国产精品久久久av美女十八| 女人爽到高潮嗷嗷叫在线视频| 亚洲精品国产区一区二| 国产一区在线观看成人免费| 亚洲熟妇中文字幕五十中出 | 色播在线永久视频| 妹子高潮喷水视频| 久热这里只有精品99| 亚洲一码二码三码区别大吗| 国产成人av教育| 国产1区2区3区精品| 久久婷婷成人综合色麻豆| 国产一卡二卡三卡精品| 天天添夜夜摸| 久久午夜亚洲精品久久| 国产成人啪精品午夜网站| av电影中文网址| 精品电影一区二区在线| 中文字幕人妻丝袜一区二区| 超色免费av| 丰满人妻熟妇乱又伦精品不卡| 精品国产国语对白av| 亚洲国产欧美日韩在线播放| 日韩欧美三级三区| 在线观看免费日韩欧美大片| 欧美人与性动交α欧美精品济南到| 久久久国产一区二区| 国产免费男女视频| 国产无遮挡羞羞视频在线观看| 十八禁网站免费在线| 国产欧美日韩综合在线一区二区| 国产成人精品久久二区二区免费| 丰满饥渴人妻一区二区三| 国产亚洲精品第一综合不卡| 国产三级黄色录像| 99精品久久久久人妻精品| 黄色怎么调成土黄色| 国产一区二区三区视频了| 亚洲,欧美精品.| 午夜福利在线观看吧| 成人三级做爰电影| 91精品国产国语对白视频| 美国免费a级毛片| 久久人人97超碰香蕉20202| 巨乳人妻的诱惑在线观看| 国产精品自产拍在线观看55亚洲| 日本wwww免费看| 日日夜夜操网爽| 999精品在线视频| 久久天堂一区二区三区四区| 免费搜索国产男女视频| 自拍欧美九色日韩亚洲蝌蚪91| 中文字幕精品免费在线观看视频| 999久久久国产精品视频| 亚洲精品粉嫩美女一区| 高清毛片免费观看视频网站 | 岛国在线观看网站| 国产一区在线观看成人免费| 亚洲一码二码三码区别大吗| 大码成人一级视频| 欧美 亚洲 国产 日韩一| av天堂在线播放| 免费高清在线观看日韩| 99久久精品国产亚洲精品| 麻豆一二三区av精品| 三上悠亚av全集在线观看| 色综合站精品国产| 亚洲一卡2卡3卡4卡5卡精品中文| 50天的宝宝边吃奶边哭怎么回事| 黑人巨大精品欧美一区二区mp4| 国产免费av片在线观看野外av| 免费搜索国产男女视频| 色尼玛亚洲综合影院| 国产99白浆流出| 99在线人妻在线中文字幕| 精品一区二区三区四区五区乱码| 黑人操中国人逼视频| 免费少妇av软件| 性色av乱码一区二区三区2| 亚洲免费av在线视频| 久久久久国产精品人妻aⅴ院| 亚洲国产看品久久| 亚洲黑人精品在线| 搡老乐熟女国产| 国产乱人伦免费视频| 黄色女人牲交| www.www免费av| 多毛熟女@视频| 在线观看66精品国产| 日韩欧美一区二区三区在线观看| 亚洲av第一区精品v没综合| 夜夜夜夜夜久久久久| 免费在线观看视频国产中文字幕亚洲| 久久欧美精品欧美久久欧美| 一个人免费在线观看的高清视频| 国产精品美女特级片免费视频播放器 | 12—13女人毛片做爰片一| 亚洲精品久久成人aⅴ小说| 精品福利永久在线观看| 亚洲第一欧美日韩一区二区三区| 不卡av一区二区三区| 国产成人系列免费观看| 免费女性裸体啪啪无遮挡网站| 少妇的丰满在线观看| 亚洲专区字幕在线| 美女大奶头视频| 天堂中文最新版在线下载| 老司机午夜福利在线观看视频| 色婷婷久久久亚洲欧美| 欧美av亚洲av综合av国产av| 国产亚洲精品久久久久5区| 首页视频小说图片口味搜索| 欧美国产精品va在线观看不卡| 亚洲国产毛片av蜜桃av| 亚洲欧美一区二区三区黑人| 精品久久久久久成人av| 女同久久另类99精品国产91| 日本精品一区二区三区蜜桃| 亚洲人成电影观看| 黑人欧美特级aaaaaa片| 亚洲人成网站在线播放欧美日韩| 宅男免费午夜| 久久香蕉激情| 9191精品国产免费久久| 国产真人三级小视频在线观看| 18美女黄网站色大片免费观看| 日日爽夜夜爽网站| 色在线成人网| 满18在线观看网站| 免费av中文字幕在线| 亚洲精品在线美女| 国产精品日韩av在线免费观看 | 两人在一起打扑克的视频| 欧美国产精品va在线观看不卡| 亚洲欧美日韩无卡精品| 香蕉丝袜av| 夫妻午夜视频| 精品一区二区三区视频在线观看免费 | 欧美大码av| 亚洲成a人片在线一区二区| 国产熟女午夜一区二区三区| 亚洲国产精品一区二区三区在线| 久久精品aⅴ一区二区三区四区| 久久久国产欧美日韩av| 午夜福利在线免费观看网站| 久久久国产成人精品二区 | av视频免费观看在线观看| 一级,二级,三级黄色视频| av片东京热男人的天堂| 亚洲中文日韩欧美视频| 亚洲成人精品中文字幕电影 | 法律面前人人平等表现在哪些方面| 亚洲欧美精品综合一区二区三区| 日本精品一区二区三区蜜桃| 人人妻人人澡人人看| 欧美性长视频在线观看| 国产av一区二区精品久久| 成年人黄色毛片网站| 亚洲精品av麻豆狂野| 最好的美女福利视频网| 久久亚洲真实| 我的亚洲天堂| 一进一出抽搐gif免费好疼 | 免费一级毛片在线播放高清视频 | 新久久久久国产一级毛片| 少妇裸体淫交视频免费看高清 | 午夜福利在线观看吧| 我的亚洲天堂| av天堂在线播放| 亚洲黑人精品在线| 欧美久久黑人一区二区| 亚洲精品在线美女| 国产一区二区三区在线臀色熟女 | 久久欧美精品欧美久久欧美| 高清黄色对白视频在线免费看| 99久久综合精品五月天人人| 中文亚洲av片在线观看爽| 精品国产一区二区三区四区第35| 俄罗斯特黄特色一大片| 少妇的丰满在线观看| 亚洲中文日韩欧美视频| 日本五十路高清| 99国产精品一区二区蜜桃av| 丰满迷人的少妇在线观看| 国产深夜福利视频在线观看| 亚洲精品中文字幕一二三四区| 男女高潮啪啪啪动态图| 嫩草影视91久久| 国产精品久久视频播放| 国产99久久九九免费精品| 天天躁夜夜躁狠狠躁躁| 日日干狠狠操夜夜爽| 亚洲精品久久午夜乱码| 无遮挡黄片免费观看| 1024视频免费在线观看| 中文字幕av电影在线播放| 一a级毛片在线观看| 亚洲五月婷婷丁香| 9191精品国产免费久久| 他把我摸到了高潮在线观看| av福利片在线| 不卡av一区二区三区| 天堂√8在线中文| 桃色一区二区三区在线观看| 中文亚洲av片在线观看爽| 日韩视频一区二区在线观看| 午夜久久久在线观看| 大型黄色视频在线免费观看| 国产成人精品久久二区二区91| 看免费av毛片| 国产真人三级小视频在线观看| 男人操女人黄网站| 日韩国内少妇激情av| 中文字幕人妻丝袜一区二区| 夜夜夜夜夜久久久久| 中文亚洲av片在线观看爽| 日韩欧美免费精品| 亚洲欧美日韩高清在线视频| 无遮挡黄片免费观看| 大香蕉久久成人网| 无限看片的www在线观看| 久久天堂一区二区三区四区| 亚洲久久久国产精品| 午夜福利欧美成人| 国产熟女午夜一区二区三区| 欧美性长视频在线观看| 女性生殖器流出的白浆| 亚洲avbb在线观看| 乱人伦中国视频| 丝袜人妻中文字幕| 搡老熟女国产l中国老女人| 亚洲aⅴ乱码一区二区在线播放 | 欧美人与性动交α欧美软件| 久久天堂一区二区三区四区| 一进一出抽搐动态| 一级黄色大片毛片| 中文字幕人妻丝袜制服| 亚洲欧美日韩高清在线视频| 亚洲国产看品久久| 99香蕉大伊视频| 国产乱人伦免费视频| 国产成人精品在线电影| 亚洲精品国产色婷婷电影| 男女午夜视频在线观看| 淫秽高清视频在线观看| 中文字幕最新亚洲高清| 亚洲自拍偷在线| 亚洲一卡2卡3卡4卡5卡精品中文| 中文字幕av电影在线播放| 国产av一区二区精品久久| 一本综合久久免费| 亚洲三区欧美一区| 日本免费a在线| 亚洲 欧美一区二区三区| 久久精品国产清高在天天线| 欧美成人免费av一区二区三区| 亚洲 国产 在线| 午夜精品在线福利| 欧美日韩精品网址| 国产精品九九99| 国产高清videossex| 亚洲自拍偷在线| 日韩有码中文字幕| 欧美成人午夜精品| 国内毛片毛片毛片毛片毛片| 国产高清国产精品国产三级| 亚洲少妇的诱惑av| 亚洲一卡2卡3卡4卡5卡精品中文| 亚洲精品成人av观看孕妇| 高清黄色对白视频在线免费看| 一级毛片精品| 免费av毛片视频| 大码成人一级视频| 久久人人97超碰香蕉20202| 国产精品成人在线| 97人妻天天添夜夜摸| 日本a在线网址| 韩国av一区二区三区四区| 久久久水蜜桃国产精品网| 正在播放国产对白刺激| 久久久久亚洲av毛片大全| 欧美精品一区二区免费开放| 在线观看免费视频日本深夜| 最近最新中文字幕大全免费视频| 在线观看舔阴道视频| 国产三级黄色录像| 国产精品一区二区免费欧美| avwww免费| 一级片'在线观看视频| 人人妻,人人澡人人爽秒播| 一区在线观看完整版| 777久久人妻少妇嫩草av网站| 日韩欧美免费精品| 美女福利国产在线| 亚洲久久久国产精品| 久久午夜综合久久蜜桃| 国产又爽黄色视频| 视频区图区小说| 丝袜在线中文字幕| 99riav亚洲国产免费| 变态另类成人亚洲欧美熟女 | 亚洲aⅴ乱码一区二区在线播放 | 久久久久久人人人人人| 日韩大码丰满熟妇| 欧美日韩av久久| 久久99一区二区三区| 一级片免费观看大全| 好看av亚洲va欧美ⅴa在| 十八禁网站免费在线| 久久久久久久久免费视频了| 午夜免费观看网址| 国产高清国产精品国产三级| 黄色女人牲交| 91麻豆av在线| 国产在线观看jvid| 精品无人区乱码1区二区| 国产精品综合久久久久久久免费 | 久久久精品欧美日韩精品| 男男h啪啪无遮挡| 亚洲熟妇熟女久久| 人人妻人人添人人爽欧美一区卜| 精品国产美女av久久久久小说| 欧洲精品卡2卡3卡4卡5卡区| 国产精华一区二区三区| 手机成人av网站| 国产成人精品久久二区二区91| 免费日韩欧美在线观看| 亚洲七黄色美女视频| 亚洲av成人一区二区三| 90打野战视频偷拍视频| 黄色a级毛片大全视频| 亚洲成av片中文字幕在线观看| 级片在线观看| 久久精品aⅴ一区二区三区四区| 色综合欧美亚洲国产小说| 搡老岳熟女国产| 成年女人毛片免费观看观看9| 亚洲成人精品中文字幕电影 | 在线十欧美十亚洲十日本专区| 亚洲九九香蕉| 色综合婷婷激情| 女性生殖器流出的白浆| 日日爽夜夜爽网站| 啦啦啦 在线观看视频| 免费一级毛片在线播放高清视频 | 亚洲av电影在线进入| 亚洲av成人一区二区三| 国产一区二区激情短视频| 亚洲中文日韩欧美视频| 女性生殖器流出的白浆| 国产激情欧美一区二区| 啦啦啦 在线观看视频| 国产成人免费无遮挡视频| 淫秽高清视频在线观看| 精品高清国产在线一区| 久久中文字幕一级| 国产精品久久久久成人av| 少妇裸体淫交视频免费看高清 | 我的亚洲天堂| a级片在线免费高清观看视频| 正在播放国产对白刺激| 日韩精品免费视频一区二区三区| 欧美一级毛片孕妇| 丁香欧美五月| 亚洲欧美精品综合久久99| 国产又色又爽无遮挡免费看| 熟女少妇亚洲综合色aaa.| 亚洲国产看品久久| 一级片'在线观看视频| 男人舔女人下体高潮全视频| av网站在线播放免费| 亚洲精品久久成人aⅴ小说| 熟女少妇亚洲综合色aaa.| 久久亚洲精品不卡| www.精华液| 欧美黑人精品巨大| 高清在线国产一区| 国产精品国产av在线观看| xxx96com| 亚洲第一青青草原| 亚洲avbb在线观看| av视频免费观看在线观看| www.熟女人妻精品国产| 国产xxxxx性猛交| 可以免费在线观看a视频的电影网站| 国产野战对白在线观看| 成人国语在线视频| 国产成人系列免费观看| 桃色一区二区三区在线观看| 亚洲国产毛片av蜜桃av| 亚洲精品国产一区二区精华液| 久久国产精品男人的天堂亚洲| 欧美一级毛片孕妇| 国产又色又爽无遮挡免费看| 99久久综合精品五月天人人| 99re在线观看精品视频| 成年女人毛片免费观看观看9| 美女大奶头视频| 自拍欧美九色日韩亚洲蝌蚪91| 80岁老熟妇乱子伦牲交| 校园春色视频在线观看| 欧美亚洲日本最大视频资源| bbb黄色大片| 国产99白浆流出| 国产极品粉嫩免费观看在线| 亚洲精品在线观看二区| 最新在线观看一区二区三区| 免费少妇av软件| 成人亚洲精品av一区二区 | 99在线视频只有这里精品首页| 超碰97精品在线观看| 欧美日韩福利视频一区二区| 最好的美女福利视频网| 久久草成人影院| 精品一品国产午夜福利视频| 国产人伦9x9x在线观看| 亚洲第一青青草原| 高潮久久久久久久久久久不卡| 女生性感内裤真人,穿戴方法视频| 看片在线看免费视频| 黑丝袜美女国产一区| 亚洲自偷自拍图片 自拍| 男女下面插进去视频免费观看| 亚洲人成网站在线播放欧美日韩| 桃红色精品国产亚洲av| 12—13女人毛片做爰片一|